US Orphan Fee Waiver Requests Must Include Much More Extensive Documentation
Executive Summary
In update of 2011 draft guidance, FDA gives more detail on documentation needed for orphan sponsors to receive a program fee waiver; Guidance also suggests the agency is no longer working with SBA to make small business determinations.
You may also be interested in...
NDA User Fees Will Climb Almost 16% On Oct. 1
US FDA completes updates for biosimilars and novel drug fee schedules as PDUFA VI is set to begin.
US FDA seeks comments on draft guidance on user fee waivers, reductions and refunds
The US Food and Drug Administration has published for stakeholder comment draft guidance on how sponsors of drugs and biologicals can request user fee waivers, refunds or reductions1,2.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.